Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.
Department of Neurosurgery, University Hospital of Larissa, School of Medicine, University of Thessaly, Larissa, Greece.
Acta Neurol Scand. 2020 Aug;142(2):108-120. doi: 10.1111/ane.13251. Epub 2020 Apr 30.
There is a possible relationship between migraine and hypercoagulability inducing factors, such as hyperhomocysteinemia. In this context, homocysteine (Hcy)-lowering vitamins (B6-folate-B12) may prove beneficial in the management-prophylaxis of migraine. We performed a systematic literature search in order to retrieve studies assessing the supplementation of B6, folate and B12 (alone or as adjunctive therapies) to migraine patients, as well as patients suffering from other primary headache disorders. MEDLINE, EMBASE, CENTRAL, Google Scholar, trial registries and OpenGrey were searched. Twelve relevant articles were retrieved. The management of acute migraine attacks with Hcy-lowering vitamins has not provided promising results (one randomized controlled trial-RCT-and one prospective uncontrolled trial). On the contrary, significant benefits were registered for the use of B6 alone, in combination with folate and in combination with folate and B12 in the prophylaxis of migraine with aura (MA) in adults compared to placebo (five RCTs, only one did not obtain significant results). Folate supplementation alone was not more efficacious than placebo (one RCT). Limited data for the prophylaxis of migraine without aura (MO) in children (two prospective uncontrolled trials) and adults (two prospective uncontrolled trials involving both MA and MO participants) impede the extraction of safe conclusions. An overall attractive safety profile was exhibited with gastrointestinal adverse events being the most common. Overall, a potential beneficial effect regarding the administration of B6, folate and/or B12 in the prophylaxis of MA in adults was indicated. Additional high-quality RCTs that will investigate MO in adults as well as MO and MA in children are warranted.
偏头痛与高凝诱导因素之间可能存在关联,如高同型半胱氨酸血症。在这种情况下,降低同型半胱氨酸(Hcy)的维生素(B6-叶酸-B12)可能对偏头痛的管理-预防有益。我们进行了系统的文献检索,以检索评估补充 B6、叶酸和 B12(单独或作为辅助治疗)给偏头痛患者以及患有其他原发性头痛疾病的患者的研究。检索了 MEDLINE、EMBASE、CENTRAL、Google Scholar、试验注册处和 OpenGrey。检索到 12 篇相关文章。使用降低 Hcy 的维生素治疗急性偏头痛发作的效果并不理想(一项随机对照试验[RCT]和一项前瞻性非对照试验)。相反,与安慰剂相比,单独使用 B6、与叶酸联合使用以及与叶酸和 B12 联合使用在预防成人有先兆偏头痛(MA)方面取得了显著益处(五项 RCT,只有一项未取得显著结果)。单独补充叶酸并不比安慰剂更有效(一项 RCT)。儿童(两项前瞻性非对照试验)和成人(两项前瞻性非对照试验涉及 MA 和 MO 参与者)预防无先兆偏头痛(MO)的有限数据阻碍了安全结论的提取。胃肠道不良事件是最常见的不良反应,总体上显示出有吸引力的安全性。总体而言,B6、叶酸和/或 B12 给药在预防成人 MA 方面可能具有潜在的有益作用。需要更多高质量的 RCT 来研究成人 MO 以及儿童 MO 和 MA。